Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia

Research output: Contribution to journalReviewpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bendtsen, Lars ; Zakrzewska, Joanna Maria ; Heinskou, Tone Bruvik ; Hodaie, Mojgan ; Leal, Paulo Roberto Lacerda ; Nurmikko, Turo ; Obermann, Mark ; Cruccu, Giorgio ; Maarbjerg, Stine. / Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. In: The Lancet Neurology. 2020 ; Vol. 19, No. 9. pp. 784-796.

Bibtex

@article{f6eaefc5c7964a3f85b717889348b1f3,
title = "Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia",
abstract = "Trigeminal neuralgia is a very painful neurological condition with severe, stimulus-evoked, short-lasting stabbing pain attacks in the face. The past decade has offered new insights into trigeminal neuralgia symptomatology, pathophysiology, and treatment, leading to a change in the classification of the condition. An accurate diagnosis is crucial because neuroimaging interpretation and clinical management differ among the various forms of facial pain. MRI using specific sequences should be a part of the diagnostic workup to detect a possible neurovascular contact and exclude secondary causes. Demonstration of a neurovascular contact should not be used to confirm a diagnosis but rather to facilitate surgical decision making. Carbamazepine and oxcarbazepine are drugs of first choice for long-term treatment, whereas microvascular decompression is the first-line surgery in medically refractory patients. Advances in neuroimaging techniques and animal models will provide further insight into the causes of trigeminal neuralgia and its pathophysiology. Development of more efficacious treatment options is highly warranted.",
keywords = "Animals, Anticonvulsants/pharmacology, Carbamazepine/pharmacology, Decompression, Surgical/methods, Disease Management, Humans, Neuroimaging/methods, Oxcarbazepine/pharmacology, Pain Measurement/drug effects, Trigeminal Neuralgia/classification",
author = "Lars Bendtsen and Zakrzewska, {Joanna Maria} and Heinskou, {Tone Bruvik} and Mojgan Hodaie and Leal, {Paulo Roberto Lacerda} and Turo Nurmikko and Mark Obermann and Giorgio Cruccu and Stine Maarbjerg",
note = "Copyright {\textcopyright} 2020 Elsevier Ltd. All rights reserved.",
year = "2020",
doi = "10.1016/S1474-4422(20)30233-7",
language = "English",
volume = "19",
pages = "784--796",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "The/Lancet Publishing Group",
number = "9",

}

RIS

TY - JOUR

T1 - Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia

AU - Bendtsen, Lars

AU - Zakrzewska, Joanna Maria

AU - Heinskou, Tone Bruvik

AU - Hodaie, Mojgan

AU - Leal, Paulo Roberto Lacerda

AU - Nurmikko, Turo

AU - Obermann, Mark

AU - Cruccu, Giorgio

AU - Maarbjerg, Stine

N1 - Copyright © 2020 Elsevier Ltd. All rights reserved.

PY - 2020

Y1 - 2020

N2 - Trigeminal neuralgia is a very painful neurological condition with severe, stimulus-evoked, short-lasting stabbing pain attacks in the face. The past decade has offered new insights into trigeminal neuralgia symptomatology, pathophysiology, and treatment, leading to a change in the classification of the condition. An accurate diagnosis is crucial because neuroimaging interpretation and clinical management differ among the various forms of facial pain. MRI using specific sequences should be a part of the diagnostic workup to detect a possible neurovascular contact and exclude secondary causes. Demonstration of a neurovascular contact should not be used to confirm a diagnosis but rather to facilitate surgical decision making. Carbamazepine and oxcarbazepine are drugs of first choice for long-term treatment, whereas microvascular decompression is the first-line surgery in medically refractory patients. Advances in neuroimaging techniques and animal models will provide further insight into the causes of trigeminal neuralgia and its pathophysiology. Development of more efficacious treatment options is highly warranted.

AB - Trigeminal neuralgia is a very painful neurological condition with severe, stimulus-evoked, short-lasting stabbing pain attacks in the face. The past decade has offered new insights into trigeminal neuralgia symptomatology, pathophysiology, and treatment, leading to a change in the classification of the condition. An accurate diagnosis is crucial because neuroimaging interpretation and clinical management differ among the various forms of facial pain. MRI using specific sequences should be a part of the diagnostic workup to detect a possible neurovascular contact and exclude secondary causes. Demonstration of a neurovascular contact should not be used to confirm a diagnosis but rather to facilitate surgical decision making. Carbamazepine and oxcarbazepine are drugs of first choice for long-term treatment, whereas microvascular decompression is the first-line surgery in medically refractory patients. Advances in neuroimaging techniques and animal models will provide further insight into the causes of trigeminal neuralgia and its pathophysiology. Development of more efficacious treatment options is highly warranted.

KW - Animals

KW - Anticonvulsants/pharmacology

KW - Carbamazepine/pharmacology

KW - Decompression, Surgical/methods

KW - Disease Management

KW - Humans

KW - Neuroimaging/methods

KW - Oxcarbazepine/pharmacology

KW - Pain Measurement/drug effects

KW - Trigeminal Neuralgia/classification

UR - http://www.scopus.com/inward/record.url?scp=85089515336&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(20)30233-7

DO - 10.1016/S1474-4422(20)30233-7

M3 - Review

C2 - 32822636

VL - 19

SP - 784

EP - 796

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 9

ER -

ID: 60922701